- Montana's right-to-try law now allows biotech companies to sell experimental drugs to any consenting consumer after a $12,500 review by a private board, bypassing FDA oversight.
- The law uniquely extends access beyond terminal illnesses to anyone willing to pay, including those seeking preventive longevity treatments.
- The review board includes a doctor, bioethicist, and longevity scientists, but critics warn of risks due to lack of FDA safety data.
- The law was driven by longevity advocates like Niklas Anzinger and state senator Ken Bogner, aiming to fast-track anti-aging drugs.
- Initial applications focus on neuropathy and hearing loss treatments, with companies drawn to Montana's business-friendly model but wary of FDA repercussions.